WLDS Stock Surges 32% on Neurorehab Pilot Approval and Warrant Price Cut

Introduction

WEARABLE DEVICES LTD (NASDAQ: WLDS) is a technology company headquartered in Yokneam Illit, Israel. Founded in 2014, the company develops AI-powered, non-invasive neural sensing wearables that translate finger and wrist movements into digital commands. Its key products, Mudra Band for Apple Watch and cross-platform Mudra Link, became commercially available in 2023, enabling touchless gesture control for both consumer and enterprise applications.

Corporate Structure and Background

Wearable Devices employs between 11 and 50 professionals in the computers and electronics manufacturing sector. The company operates a dual-channel model targeting both business-to-consumer (B2C) and business-to-business (B2B) markets. The B2C channel is represented by Mudra Band, which utilizes surface electromyography (sEMG) sensors and AI technology to control Apple ecosystem devices. The B2B channel includes licensing agreements and a Mudra Developer Kit, enabling partners and original equipment manufacturers (OEMs) to incorporate neural input capabilities into augmented and extended reality (AR/XR) products, wellness applications, and other hardware platforms. Strategic partnerships with Qualcomm, TCL-RayNeo™, and Media Exceed support the company’s global commercialization efforts.

Wearable technology by Luke Chesser

Recent Developments and News

• On December 11, 2025, the board approved a $750,000 budget for a neurorehabilitation pilot project with Soroka Medical Center, aimed at validating Mudra Link as a rehabilitation tool for impaired grip-force control following motor-cortex injuries.
• On December 17, 2025, Wearable Devices filed an amended F-1 registration statement with the SEC for the offering of up to 1,670,000 ordinary shares, including warrants. The amendment proposes reducing the exercise price of two warrant tranches from $4.00 and $6.00 to $2.67 per share, pending shareholder approval.
• On December 4, 2025, the company submitted a Form D notice for an exempt offering of securities under Regulation D, indicating an ongoing effort to raise capital through private placements.
• U.S. patent allowances granted in December 2025 advance the company’s neural sensing and gesture-control technologies, while partnerships in Japan and South Korea aim to expand market reach within the wearable device sector.

Financial and Strategic Analysis

As of December 24, 2025, WLDS shares closed at $1.81, representing a 32.12% increase on a volume of 1,234,331 shares (average daily volume: 500,939). The market capitalization is approximately $13.1 million. Key trailing twelve-month metrics (as reported by Yahoo Finance include):

• Revenue: $422,000
• Net loss: $7.38 million
• Diluted EPS: –$9.98
• Price/Sales ratio: 3.03
• Price/Book ratio: 3.22
• Total cash on hand: $3.46 million
• Debt/Equity: 4.28%
• Beta (5Y monthly): 3.60

The pending F-1/A share and warrant offering, along with the Form D private placement, indicate a strategy to raise capital to support product development, clinical validation, and market expansion. The company’s dual-channel approach and evolving patent portfolio aim to strengthen its positioning in the neural input wearables market.

Market Position and Industry Context

Wearable Devices operates at the intersection of human-computer interaction, biometrics, and spatial computing. Its products have received recognition from CES Innovation Awards (Mudra Band in 2021, Mudra Link in 2025) and are applicable in areas such as biometric security, robotics, defense, sports analytics, and automotive systems. As advancements in AR glasses, XR headsets, and predictive health monitoring continue, the company aims to leverage its neural data intelligence platform to secure OEM licenses and enterprise partnerships. Competing technologies include touchscreens, motion sensors, and voice interfaces; Wearable Devices’ sEMG-based approach offers an alternative control layer that does not require physical contact.

tl;dr

WLDS shares rose 32.12% to $1.81 on December 24, 2025. The company authorized a $750,000 neurorehabilitation pilot with Soroka Medical Center on December 11, 2025. The December 17, 2025 F-1/A filing seeks to offer up to 1.67 million shares and reduce existing warrant exercise prices to $2.67 pending a vote. A December 4, 2025 Form D notice indicates a private placement round. U.S. patent allowances and partnerships in Asia support clinical validation, product refinement, and market entry in 2026.